Autopsy report · NCT02431260

An Open-Label, Dose-Escalation Study of INCB054329 in Patients With Advanced Malignancies

“As of 31 JAN 2018, the study was terminated by the sponsor due to PK variability.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 10 months before it stopped.
• 69 participants enrolled.
• Results were posted on the registry 1 year 4 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 1, Phase 2

Sponsor

Incyte Corporation

Sponsor type

Industry

Conditions

Solid Tumors and Hematologic Malignancy

Interventions

INCB054329 Monotherapy

Participants

69

Sites

12

Countries

United States

Trials that died the same way

• Long-term, Non-interventional, Observational Study Following Treatment With Fate Therapeutics FT500 Cellular Immunotherapy
  “This study was terminated by the Sponsor.” (80% match in meaning)
• A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
  “The study was terminated early as per Sponsor's decision” (79% match in meaning)
• Trial of Erlotinib in Patients With JAK-2 V617F Positive Polycythemia Vera
  “The study was terminated by the sponsor” (78% match in meaning)
• Prospective Case-Series of Ligasure Advance Pistol Grip and LigaSure Blunt Tip
  “The Sponsor terminated the study.” (77% match in meaning)
• Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers
  “After recruitment of Cohorts 1-4 was completed, Sponsor decided to terminate study, initially due to COVID and then considering that PK data from the dose planned to be tested in Cohort 5 (18000 mg) would be available from the ongoing Phase 3 study.” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.